解码胃腺癌中 MUC3A 的表达模式：揭示成功免疫疗法的关键所在

IF 4.6 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-08 DOI:10.1080/14728222.2023.2293764

Masoud Sotoudeh, Vahid Mansouri, Ramin Shakeri, Bahareh Sharififard, Nasim Sajadi, Vahid Haghpanah, Mahmood Naderi

引用次数: 0

摘要

尽管免疫疗法有望治疗胃腺癌，但耐药性很常见，因此有必要验证新的靶点。根据我们之前的生物信息学分析，MUC3A 抗原 ...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Decoding the expression pattern of MUC3A in gastric adenocarcinoma: unveiling the key to successful immunotherapy

Despite the promise of immunotherapy for gastric adenocarcinoma, resistance is common, necessitating the validation of new targets. Based on our previous bioinformatics analysis, the MUC3A antigen ...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Opinion on Therapeutic Targets 医学-药学

CiteScore

8.90

自引率

1.70%

发文量

审稿时长

3 months

期刊介绍： The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.